Recent News

• 03.07.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.12.2025 - Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
• 02.12.2025 - Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
• 02.12.2025 - Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
• 02.07.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.07.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.07.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.07.2025 - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 03.07.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 3 Initial statement of beneficial ownership of securities
• 03.07.2025 - 8-K Current report
• 03.07.2025 - 3 Initial statement of beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 8-K Current report
• 02.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]